Healthcare Industry News: oral mucositis
News Release - May 15, 2007
Senior Development Executive Joins SerenexStrengthens Drug Development Team to Advance Clinical Pipeline
DURHAM, NC--(Healthcare Sales & Marketing Network)--May 15, 2007 -- Serenex, Inc., an integrated oncology-focused drug discovery and development company, announced today the appointment of Judith C. Bryson Pharm.D. to the position of vice president, clinical development. Dr Bryson will be responsible for all aspects of clinical development and will serve as a member of the company's senior management team.
"We are extremely pleased to have Judy join Serenex. She brings a wealth of senior level oncology clinical development experience and leadership to the company. We have a number of exciting and important oncology programs underway and Judy's experience will be essential in moving them through the clinic," said Dr. Richard Kent, president and chief executive officer at Serenex.
"I am excited to be joining a company with such clearly differentiated products which could each potentially bring compelling new therapies and treatments to oncology patients," said Dr. Judith C. Bryson.
Dr. Bryson joins Serenex from Pozen, Inc. where she held the position of vice president, clinical development. In this position, Dr. Bryson was responsible for all clinical development activities from proof-of-concept to NDA submission. Prior to that, Dr. Bryson spent several years with EMD Pharmaceuticals, Inc. (now EMD-Serono) as Global Product Team Leader, Oncology and at Glaxo Wellcome, Inc. where she held the position of Therapeutic Director, Oncology and HIV, US Medical Affairs.
Serenex is an integrated oncology-focused drug discovery and development company. Serenex's lead program, SNX-1012, a product for chemotherapy and radiation-induced oral mucositis in solid tumor patients, is scheduled to complete phase 2 clinical trials at the end of 2007. oral mucositis, which represents a large and underserved market, frequently causes clinicians to interrupt therapy which directly leads to decreased rates of efficacy. Additionally, Serenex has a novel, orally bioavailable small molecule inhibitor of Heat Shock Protein 90 (Hsp90) commencing phase 1 clinical trials in the second quarter of 2007. Hsp90 is a central protein responsible for chaperoning a large number of oncogenic proteins (such as Her2 and Raf) that are necessary to support cancer cell survival and growth. Serenex's pipeline is powered by a proprietary high throughput screening platform which enables the company to profile compounds, en masse, against thousands of important therapeutic and toxicity targets. Website: www.serenex.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.